There are currently 189 clinical trials in Sarasota, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Sarasota Memorial Hospital, Florida Cancer Specialists, GSK Investigational Site and Sarasota Retina Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
NCT05668585
Recruiting
The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B) or Cetuximab (CFT1946 + cetuximab; Arm C).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Solid Tumors, Melanoma, NSCLC, CRC, ATC
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk r... Read More
Gender:
Female
Ages:
Between 35 years and 50 years
Trial Updated:
05/01/2024
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida +5 locations
Conditions: Ovarian Carcinoma
Register for Updates
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417
Recruiting
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: Find the recommended dose of IMT-009 that can be safely given to participants Learn more about the side effects of IMT-009 Learn more about pharmacokinetics of IMT-009 Learn more about the effectiveness of IMT-009 Learn more about different pharmacokinetic b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Site 4060, Sarasota, Florida
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma
Register for Updates
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423
Recruiting
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Ovarian Cancer, Solid Tumor
Register for Updates
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of sEphB4-HSA in Kaposi Sarcoma
NCT03993106
Recruiting
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: CAN (Community AIDS Network) Community Health, Sarasota, Florida
Conditions: Kaposi Sarcoma
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: At a dose of 120µg. In adults 60 years of age and older. The duration of the study for each participant will be up to approximately 24 months. The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This study is... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
04/29/2024
Locations: Headlands Research Sarasota, Sarasota, Florida
Conditions: Lower Respiratory Tract Illness
Register for Updates
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
NCT03449381
Recruiting
This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate. The most suitable dose is used in the second part to find out whether brigimadlin makes tumors shrink. In this study, brigimadlin is given to humans for the first time. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Brigimadlin is taken as a tablet. Partic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Neoplasms
Register for Updates
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT05765851
Recruiting
This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor, Breast Cancer
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/26/2024
Locations: Sarasota Memorial Health Care System, Sarasota, Florida
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05585034
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Covenant Research and Clinics, LLC, Sarasota, Florida
Conditions: Primary Biliary Cholangitis, PBC
Register for Updates